## SUPPLEMENTARY INFORMATION

# Computational design and molecular dynamics simulations suggest the mode of substrate binding in ceramide synthases

Iris D. Zelnik<sup>1</sup>, Beatriz Mestre<sup>1</sup>, Jonathan Weinstein<sup>1</sup>, Tamir Dingjan<sup>1</sup>, Stav Izrailov<sup>1</sup>, Shifra Ben-Dor<sup>2</sup>, Sarel J Fleishman<sup>1</sup> and Anthony H. Futerman<sup>1\*</sup>

From the <sup>1</sup>Department of Biomolecular Sciences and <sup>2</sup>Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot 76100, Israel

\* To whom correspondence should be addressed at tony.futerman@weizmann.ac.il

## Contents

Supplementary Table 1. RMSDs for AlphaFold2 CerS models. Supplementary Table 2. Percent sequence similarity and identity between human CerS proteins. Supplementary Table 3. Composition of the ER-like membrane used in MD simulations. Supplementary Figure 1. The highly conserved residue, Trp 327 is critical for CerS activity. Supplementary Figure 2. Sequence alignment of WT and mPROSS designs. Supplementary Figure 3. CerS stabilization by mPROSS. Supplementary Figure 4. Acyl-CoA specificity of CerS2 d18 is similar to the WT. Supplementary Figure 5. RMSD of the TMDs of CerS2 during production-stage MD simulation. Supplementary References **Supplementary Table 1.** RMSD values (Å) of AlphaFold2 CerS models for superimposition of the structures of the full-length protein (above the diagonal) and for the TMDs (below the diagonal).

	CerS1	CerS2	CerS3	CerS4	CerS5	CerS6	Full length- Protein RMSD
CerS1		2.02	1.35	0.86	2.18	1.72	CerS1
CerS2	1.06		0.53	0.56	0.67	0.64	CerS2
CerS3	0.93	0.37		0.74	0.66	0.80	CerS3
CerS4	0.75	0.39	0.41		0.56	0.59	CerS4
CerS5	0.95	0.47	0.50	0.46		0.43	CerS5
CerS6	0.88	0.51	0.52	0.51	0.30		CerS6
TMD RMSD	CerS1	CerS2	CerS3	CerS4	CerS5	CerS6	

**Supplementary Table 2.** Percent sequence similarity (below the diagonal) and identity (above the diagonal) between human CerS proteins.

	CerS1	CerS2	CerS3	CerS4	CerS5	CerS6	Identity
CerS1		21.8	20.4	24.4	23.2	24.6	CerS1
CerS2	35.6		52.1	47.6	40.1	40.9	CerS2
CerS3	35.8	70.7		42.3	39.0	38.5	CerS3
CerS4	37.0	66.3	61.0		40.4	40.5	CerS4
CerS5	35.4	57.9	57.0	58.1		61.8	CerS5
CerS6	35.5	60.4	57.4	59.0	78.1		CerS6
Similarity	CerS1	CerS2	CerS3	CerS4	CerS5	CerS6	

# Supplementary Table 3. Composition of the ER-like membrane used in MD simulations.

Lipid names correspond to the CHARMM forcefield convention. Counts are given as the total number of molecules of each lipid species in the cytoplasmic and ER lumenal leaflets<sup>1,2</sup>. Some caution needs to be taken when considering ER lipid composition due to the high likelihood of contamination from other intracellular organelles; however the composition below is currently the best approximation of ER lipid composition.

	Cytoplasmic	ER lumenal
	leaflet	leaflet
	(number of	(number of
Lipid	lipids)	lipids)
SOPA	2	2
DPPA	2	2
SLPC	34	10
SOPC	20	6
PYPC	18	5
SLPE	18	28
SOPE	10	16
POPE	9	14
SOPS	8	29
POPS	2	7
SLPS	2	6
SLPG	10	10
DGPG	5	5
DEPG	5	5
PSM	25	13
NSM	9	5
LSM	10	8
Cholesterol	20	20
TOTAL	207	189



#### Supplementary Fig. 1. The highly conserved residue, Trp 327 is critical for CerS activity.

Homogenates (50 µg of protein) were prepared from WT HEK cells overexpressing WT or CerS5<sup>W327A</sup>. Activity was measured using 1 µg of protein and C16-CoA for 5 min. Results are means  $\pm$  S.D., n = 3 for CerS5 constructs and n=2 for the empty plasmid (pcDNA). Levels of protein expression, ascertained by western blotting using an anti-HA antibody and anti-tubulin as a loading control, are shown. Molecular weight markers are indicated. Results are of a single experiment, repeated three times with similar results. Source data are provided as a Source Data file.

CERS2 WT	1	MLQTLYDYFWWERLWLPVNLTWADLE-DRDGRVYAKASDLYITLPLALLFLIVRYFFELYVATPLAALLNIKE
CERS2 D5	1	MLQTLYDYFWWERLWLPVNLTWADLE-DRDGRVYAKASDLYITLPLALLFLI <mark>IRF</mark> FFEL <mark>F</mark> VATPLA <mark>R</mark> LLNIKE
CERS2 D10	1	MLQTLYDYFWWERLWLPVNLTWADLE-DRDGRVYAKASDLYITLPLALLFLI <mark>IR</mark> FFFEL <mark>F</mark> VATPLA <mark>R</mark> LLNIKE
CERS2 D13	1	MLOTLYDYFWWERLWLPVNLTWADLE-DRDGRVYAKASDLYITLPLALLFLI <mark>TR</mark> FFELFVATPLARLLNIKE
CERS2 D18	1	MLOTLYDYFWWERLWLPVNLTWADLE-DRDGRVYAKASDLYLTLPLALLFLITRFLFERFTATPLARLLNIKE
CERS5 WT	1	MATAAOGPL.S.I.W.GWLWSERFWLPENVSWADLEGPADGYGYPRGRHILSVFPLAAGIFFVRLLFERFIAKPCALCIGIED
CERS5_D5	1	MATAAOGPLSLIWGWIWSERFWIPENVSWADLEGPADGYGYPRGRHILSVFPLALGIFFTRILFERFIAKPCALCIGIED
CERS5 D13	1	MATAAOGDISI.MCMIMSEBEWI.DENVSWADI.ECDADCYCYDRCRHIISVEDIALCIEFI.I.FERFIAKDCAL
CERS5 D18	1	MATABOCHI, SILIWOWI WSERFWI DENVSWANI ECDADCYCYDRCRHI SVEDIAI CIFET PLI FERFIAKDIAI DI CIFD
	-	* * • • • * * * • • * * • • * * * * * *
CERS2 WT	73	KTRLRAPPNATLEHFYLTSGKOPKOVEVELLSROSGLSGROVERWFRRRRNODRPSLLKKFREASWRFTFYLTAFTAGMA
CERS2 D5	73	KTRIBADDNATIEHEVITSCKOKOVEVELISBOSCISCBOVERWERRRRNODRDSLIKKEREASWRFTEVITAFIACIA
CERS2_D0	73	KTDI DADDNOTI FUFVI TSCKOKOSTOFI I SKOSCI SCDOVEDWEDDDNODDSI I KKEDEASWDETEVI IAFIACIA
CERS2_DIO	73	
CERS2_DIS	73	
CERSZ_DIO	01	ALKLERAPPNELIDERFIDISGROUPRESEVEDLARQSGLISGROVERWIR KRKRRUDDERSDLING KEAR WRTEFIDIAFIAG
CERSS_WI	01	SGP IQAQPNAILEKVFISITATPDARALEGISKQLDWNVRAIQCWFRAKKNQDAPPIIIRFCESMWPRIFILCFCIGIK
CERS5_D5	81	SGPIQAQPNAILEKVFISITKIPDKKLEGLSKQLDWNVKIQCWFKHRKNQDKPPTLTKFCESMWRFTFILCIFCIGIR
CERS5_D13	81	SGPYQAQPNAILEKVFISITKYPDKKRLEGSKQLDWDVRKIQCWFRHRRNQDKPPTLTKFCESMWRFTFYLCIFCYGIR
CERS5_D18	81	SGPYQAQPNPILEKVFITIITKYPDQKRLEGLAKQLDwDvRKIQCWFRHRRNQDKPPTLTKFCESMWRFTFYLFIFIFGLR
		. :* **. **:. ::: * *.: .:* *::* *::: ***:****:*. *.** *: *** ***
CERS2_WT	153	VIVDKPWFYDMKKVWEGYPIQSTIPSQYWYYMIELSFYWSLLFSIASDVKRKDFKEQIIHHVATIILISFSWFANYIRAG
CERS2_D5	153	VIVDKPWFYDMKKVWEGYPIQSTIPSQYWYYMIELSFYWSLLFSIASDVKRKDFKEQIIHH <mark>L</mark> ATIILISFSWFANYIRAG
CERS2_D10	153	VIVDKPWFYDMKKVWEGYPIQSTIPSQYWYYMIELSFYWSLLFSIASDVKRKDFKEQIIHH <mark>L</mark> ATIILISFSWFANYIR <mark>V</mark> G
CERS2_D13	153	VIVDKPWFYDMKKVWEGYPIQSTIPSQYWYYMIEL <mark>A</mark> FYWSLLFSIASDVKRKDFKEQIIHH <mark>L</mark> ATIILISFSWFANYIR <mark>V</mark> G
CERS2_D18	153	VI <mark>I</mark> DKPWF <mark>W</mark> DM <mark>R</mark> KVWEGYPIQSTIPSQYWYYM <mark>L</mark> EL <mark>A</mark> FYWSLLFSIASDVKRKDFKEQIIHH <mark>L</mark> ATIILISFSWFANYIR <mark>I</mark> G
CERS5_WT	161	$\label{eq:second} FLWSSPWFWDIRQCWHNYPFQPLSSGLYHYYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVGPLSSGLYHYYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVGPLSSGLYHYYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVGPLSGLYHYYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVGPLSGLYHYYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVGPLSGLYHYYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVGPLSGLYHYYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVGPLSGLYHYYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVGPLSGLYHYYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVGPLSGLYHYYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVGPLSGLYHYYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVGPLSGLYHYYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVGPLSGLYHYYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVGPLSGLYHYYIMELAFYWSLMFSQFTDIKRKDFLIMFVHITTGTTGTTGTTTTTTTTTTTTTTTTTTTTTTTTTTTT$
CERS5_D5	161	FLWSSPWFWDIRQCWHNYPFQPLSSGLY <mark>W</mark> YYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVG
CERS5_D13	161	FLWSSPWFWDIRQCWHNYPFQPLSSGLY <mark>W</mark> YYIMELAFYWSLMFSQFTDIKRKDFLIMFVHHLVTIGLISFSYINNMVRVG
CERS5_D18	161	FLW <mark>L</mark> SPWFWDIRQCW <mark>Y</mark> NYPFQPL <mark>T</mark> SGLY <mark>W</mark> YYI <mark>L</mark> ELAFYW <mark>A</mark> L <mark>F</mark> SQFTDIKRKDFLIMFVHHLVTIGLI <mark>C</mark> FSYINNMVR <mark>L</mark> G
		.: .***:*:: * .**:* * **::**:***:** :*:********
CERS2_WT	233	TLIMALHDSSDYLLESAKMFNYAGWKNTCNNIFIVFAIVFIITRLVILPFWILHCTLVYPLELYPAFFGYYFFNSMMGVL
CERS2_D5	233	TLIMALHDSSDYLLESAKMFNYAGWKNTCNNIFIVFAIVFIITRLVILPFWIL <mark>Y</mark> CTLVYPLELYPAFFGYYFFNSMMGVL
CERS2 D10	233	TLIMALHDSSDYLLE <mark>A</mark> AKMFNYAGWKNTCNNIFIVFAIVFIITRLVILPFWIL <mark>Y</mark> CTLVYPLELYPAFFGYYFFNSMMG <mark>L</mark> L
CERS2 D13	233	TLIMALHDSSDYLLE <mark>A</mark> AKMFNYAGWKNTCNNIFIVFAIVFIITRLVILPFWIL <mark>Y</mark> CTLVYPLELYPAFFGYYFFN <mark>L</mark> MMG <mark>L</mark> L
CERS2 D18	233	TLIMALHDAADYLLELAKMFNYAGWKNTCNNIFIVFAIVFIITRLIIPLWILYCTLVYPLELYPPFFGYWFFNLLMGI
CERS5 WT	241	TLIMCLHDVSDFLLEAAKLANYAKYORLCDTLFVIFSAVFMVTRLGIYPFWILNTTLFESWEIIGPYASWWLLNGLLLTL
CERS5 D5	241	TLIMCLHDVSDFLLEAAKLANYAKYQRLCDFLFVIFS <mark>I</mark> VF <mark>FI</mark> TRLGIYPFWILNTTLFESWEIIGPYASWWLLNGLLL <mark>I</mark> L
CERS5 D13	241	TLIMCLHDVSDFLLEAAKLANYAKYORLCDLLFVIFATVFFITRLGIYPLWILWTTLFESWEIIGPYASWWLLNGLLLL
CERS5 D18	241	TL <mark>VML</mark> LHDV <mark>A</mark> DFLLEAAKLANYAKWORLCDLLFVIF <mark>AI</mark> VF <mark>FI</mark> TRLGIYPLWIL <mark>Y</mark> TTL <mark>I</mark> ESWEIIGPYASWWLLNGLLL <mark>I</mark> L
_		***** *** ****** ***: *** *************
CERS2 WT	313	QLLHIFWAYLILRMAHK-FITGKLVEDERSDREETESSEGEEAAAGGGAKSRPLANGHPILNNNHRKND
CERS2 D5	313	OLLHIFWAYLILRMAHK-FITGKLVEDERSDREETESSEGEEAAAGGGAKSRPLANGHPILNNNHRKND
CERS2 D10	313	OLLHIFWAFLILRMAHK-FITGKLVEDERSDREETESSEGEEAAAGGGAKSRPLANGHPILNNNHRKND
CERS2 D13	313	OLLHIFWAFLILRMAHK-FITGKLVEDERSDREETESSEGEAAAGGGAKSRPLANGHPILNNNHRKND
CERS2 D18	313	
CERS5 WT	321	CILHUTWSYLIARTALKALINGKVSKDDRSDVESSSEEDDTTCTKSPORGSSKANT BANGINT DA MININND
CERS5 D5	321	
CERS5 D13	321	ZILIH TWARLITR TALKALI TRCKVCKDDRSDVESSSEEED VITCIKS CODS SOCKAKI VIGHIGGO WAEE
CERS5 D19	321	
CER22_DI0	521	VULITE WAR DIENTRALANDING VOLDAND VESSEELE VIIGING FOLS-SSSINGANAVNGANGGSIWALE

**Supplementary Fig 2. Sequence alignment of WT and mPROSS designs.** Amino acid multiple sequence alignment of mPROSS designed variants of CerS2 and CerS5 together with that of WT controls (CLUSTALW multiple alignments). The consensus line below the aligned sequences indicates positions of conserved amino acid where the asterisks (\*) indicate identical residues, colons (:), and periods (.) indicate similar residues, with colons indicating higher similarity than periods. Mutations introduced by mPROSS are highlighted in *yellow*. Altogether 18 designs were obtained by mPROSS for each CerS, of which 4 were generated, expressed and tested for activity for CerS2 and 3 for CerS5.



**Supplementary Fig 3. CerS stabilization by mPROSS.** Yellow spheres denote mutated positions. 37 and 41 substitutions were introduced in d18 of CerS2 and CerS5, respectively. Some mutations improve interhelical core packing and remove cavities (center panels). Many mutations increase lipophilicity (*right-hand* panels). Mutations are shown in yellow, wild type residues in grey.



# Supplementary Fig. 4. Acyl-CoA specificity of CerS2 d18 is similar to the WT. (A)

Homogenates (40  $\mu$ g of protein) from HEK<sup>CerS2-/-</sup> cells overexpressing an empty vector, WT or d18 CerS2, were assayed using the indicated acyl-CoA for 25 minutes. Results are means ± S.D., n = 3. (B) CerS2 expression ascertained by Western blotting using an anti-HA antibody. An anti-PCNA antibody was used as loading control. Molecular weight markers are indicated. Results are of a single experiment, repeated three times with similar results. Source data are provided as a Source Data file.



**Supplementary Fig. 5**. RMSD (Å) of the CerS2 TMD during production-stage MD simulations. RMSD was calculated with translation and rotation to compare the protein structure at each frame with the reference protein structure at the beginning of simulation. Source data are provided as a Source Data file.

### **Supplementary References**

1. Andreyev, A. Y. *et al.* Subcellular organelle lipidomics in TLR-4-activated macrophages. *J Lipid Res* 51, 2785–97 (2010).

2. Bollen, I. C. & Higgins, J. A. Phospholipid asymmetry in rough- and smooth-endoplasmic-reticulum membranes of untreated and phenobarbital-treated rat liver. *Biochem J* 189, 475–480 (1980).